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Abstract
Germinal heterozygous activating STAT3 mutations represent a novel monogenic defect associated 
with multi-organ autoimmune disease and, in some cases, severe growth retardation. By using 
whole-exome sequencing, we identified two novel STAT3 mutations, p.E616del and p.C426R, in 
two unrelated pediatric patients with IGF-I deficiency and immune dysregulation. The functional 
analyses showed that both variants were gain-of-function (GOF), although they were not 
constitutively phosphorylated. They presented differences in their dephosphorylation kinetics and 
transcriptional activities under interleukin-6 stimulation. Both variants increased their 
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transcriptional activities in response to growth hormone (GH) treatment. Nonetheless, STAT5b 
transcriptional activity was diminished in the presence of STAT3 GOF variants, suggesting a 
disruptive role of STAT3 GOF variants in the GH signaling pathway. This study highlights the 
broad clinical spectrum of patients presenting activating STAT3 mutations and explores the 
underlying molecular pathway responsible for this condition, suggesting that different mutations 
may drive increased activity by slightly different mechanisms.
Keywords
STAT3; IGF-I deficiency; Growth hormone insensitivity; Activating mutations; Immune 
dysregulation
1. Introduction
Growth failure associated with severe primary insulin-like growth factor 1 (IGF-I) deficiency 
is characterized by an insufficient production of IGF-I, notwithstanding adequate secretion 
of growth hormone (GH). The classic form of severe primary IGF-I deficiency (IGFD) is 
Laron syndrome, where a homozygous or compound heterozygous mutation in the gene 
encoding the GH receptor (GHR) leads to low or undetectable IGF-I levels (Laron, 2015). 
Other well defined causes of IGFD are defects in genes encoding post-GHR signaling 
components, including the signal transducer and activator of transcription (STAT)-5b 
(Kofoed et al., 2003), the IGF-I (Woods et al., 1996) and the acid-labile subunit (ALS) 
(Domené et al., 2004). Recently, activating mutations in the STAT3 gene were described in 
children with severe growth failure associated with a spectrum of early-onset autoimmune 
disease, including type I diabetes, enteropathy, autoimmune cytopenia, hypothyroidism, 
arthritis, and interstitial lung disease (Flanagan et al., 2014; Haapaniemi et al., 2015; Milner 
et al., 2015). STAT3 is a cytosolic protein involved in intracellular signaling transduction 
from cytokines, including several interleukins (IL), interferons (IFN α/β and γ) and growth 
factors (Mogensen, 2013). It contains several domains, a coil-coiled, a DNA binding, a SH2 
and a transactivation domain and it is involved in many biological processes, such as cell 
growth, apoptosis, organogenesis, inflammation, infection and oncogenesis (Akira, 2000). 
Response to cytokines and growth factors is mediated by JAK activation, which in turn, 
phosphorylates specific tyrosine residues of the receptor. The phosphotyrosine residues 
constitute the docking site for the SH2 domain of the STAT3 protein, leading to JAK-
mediated STAT3 phosphorylation and dimer formation. STAT3 dimers translocate to the 
nucleus, bind to DNA and induce gene transcription (Groner, 2012). Activating STAT3 
germline mutations are located in the DNA-binding, SH2, transactivation or coiled-coil 
domains.
We report two novel heterozygous de novo STAT3 mutations in two unrelated patients with 
severe growth failure and IGF-I deficiency. We have evaluated the effects of these variants 
on the endocrinological and the immunological system and characterized the in vitro 
functional activities in response to GH and IL-6 stimuli. In addition, we studied how these 
mutants affect STAT5b function in the GH-signaling pathway.
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2. Subjects and methods
2.1. Case reports
2.1.1. Patient 1—Patient 1 was a female, the second daughter from healthy non 
consanguineous parents of normal height, born at term with normal weight (3.155 g, −0.18 
SDS) and low birth length (44 cm, −2.76 SDS) (Table 1). Congenital autoimmune 
hypothyroidism was diagnosed with anti-thyroid antibodies persistently positive since birth. 
In the first two years of life she developed descamative eczema, chronic diarrhea, an episode 
of Citrobacter spp urinary tract infection, recurrent oral candidiasis, lymphocytic interstitial 
pneumonia with non-necrotizing granulomas associated with severe respiratory infections 
that required permanent oxygen supply and over 30 hospitalizations. She was referred to the 
pediatric endocrinologist at 2.4 years of age, when she presented a height of −6.4 SD. The 
immunological evaluation showed IgG levels between −1 and −2 SDS for age, with elevated 
IgA (>2 SDS), normal IgM and non-detectable IgE levels (Table 1). Lymphocyte subsets, 
including CD3+, CD4+, CD8+, CD19+, CD3−, CD56+ and regulatory T cells (CD4+ 
CD25++CD127lowFOXP3+ Tregs), were normal. Her cytokine profile revealed absence of 
Th17 with CD4+ T cells skewed to Th2. The patient also had elevated prolactin and GH 
serum levels, associated with non-detectable IGF-I and normal IGFBP-3 levels. She 
underwent an IGF generation test with recombinant human (rh) GH (33 mg/kg.day) for 7 
days which showed a limited increase in IGF-I and normalization of IGFBP-3 levels (Table 
1). She received levothyroxine treatment since 20 days of age and started rhGH treatment 
(0.43 mg/kg.wk) at 2.5 years, gaining 1.4 SDS in 2 years of treatment and increasing IGF-I 
levels to 240 ng/mL (Supplementary Fig. 1). She also received oral meprednisone, 
prophylactic trimethoprimsulfamethoxazole and intravenous γ globulin treatments. At the 
age of 3.2 years, oral sirolimus was added but was replaced by oral cyclosporine because of 
lymphedema complications. The patient died at 4 years of age, 18 days after a bone marrow 
transplantation with a matched unrelated donor due to a multiple organ failure.
2.1.2. Patient 2—Patient 2 was a male, the second child from non consanguineous 
parents, born at term with normal weight and birth length (Table 1). His parents and older 
brother are of normal stature and healthy. At 2 weeks of life the patient was hospitalized for 
RSV bronchiolitis with hypoxia. In the first two years of life, he developed failure to thrive 
associated with chronic, intractable diarrhea, intermittent vomiting, abdominal distention, 
and severe eczema. Endoscopy at 2 years of age indicated marked lymphocytic gastritis and 
basal cell hyperplasia of the esophagus and stomach consistent with gastritis; mild lymphoid 
nodularity was observed in the duodenum. Acquired hypothyroidism was diagnosed at age 
2, and levothyroxine (L-T4) therapy was started. At the age of 3, his height was −5.4 SD. 
Prior treatments included topical tacrolimus, sulfasalazine, inhaled corticosteroids, 
bronchodilators and proton pump inhibitors. He was also treated with a variety of immune-
suppressive agents including prednisolone, Sirolimus, and Abatacept, all with minimal 
response. Growth improved but remained poor. The immunological phenotype was similar 
to that of Patient 1 (Table 1) with normal IgG and IgM levels, high IgA and non-detectable 
IgE levels. Lymphocyte subsets, including FOXP3+, Tregs and Th17 were all normal. 
Endocrine evaluation was remarkable for relatively high GH serum levels, normal prolactin, 
undetectable IGF-I and low IGFBP-3 levels. The patient’s hypothyroidism was not well-
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controlled. TSH values rarely normalized despite L-T4 supplementation of ~5 mcg/kg/day. 
At age 6, the patient passed a pseudo-malabsorption test suggesting non-adherence to 
prescribed L-T4 therapy rather than malabsorption of thyroxine compound. At age 7, he was 
started on rhGH (0.3 mg/kg/day) showing a partial response with gain of height SDS from 
−2.90 to −2.48 within 1.4 years of treatment. IGF-I has normalized to near 10–25thcentile 
for age. Previous gain in height SDS from −5.4 was attributed to thyroxine and immunologic 
treatments.
2.2. Molecular studies
Genomic DNA from patients and relatives was extracted from venous peripheral blood (Del 
Sal et al., 1989). Using a candidate gene approach, STAT5B and FOXP3 genes were 
analyzed for P1 and P2 respectively, by PCR amplification followed by Sanger sequencing. 
Whole Exome Sequencing for patient 1 was performed using Illumina HiSeq1500 at the 
Instituto de Agrobiotecnología de Rosario (INDEAR)-CONICET (Rosario, Argentina) in a 
quartet-design, including the index case, her parents, and her healthy sister, using Illumina 
Nextera Exome V1.2 kit (45 Mb - 214,405 exons) for exome capture. WES for Patient 2 and 
unaffected parents was performed through the DNA Sequencing and Genotyping Core at 
Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio, USA), employing 
Illumina HiSeq2500. Stringent filtering strategies for analyzing WES data include 
population frequency, pattern of inheritance, and specific filters for immune candidate genes. 
STAT3 likely pathogenic variants were identified in the index cases, and confirmed by 
Sanger sequencing in patients and family members (primers used are available upon 
request).
2.3. In silico bioinformatics analysis
STAT3 variants were analyzed in silico to predict their effects on protein function. For this 
purpose, different bioinformatics tools were used: PolyPhen-2 (Adzhubei et al., 2010), SIFT 
(Kumar et al., 2009), Mutation Taster (Schwarz et al., 2014), MutPred (Li et al., 2009), and 
SNAP2 (Hecht et al., 2015). The following NCBI reference sequences were used: 
NG_007370.1 (gene), NM_139,276.2 (mRNA) and NP_40,763.1 (protein). Different 
databases were used to evaluate the presence of the STAT3 variants found in the patients: 
dbSNP (the NCBI database for Short Genetic Variation, http://www.ncbi.nlm.nih.gov/SNP/
snp_ref.cgi?locusId 3483), COSMIC (the Catalogue Of Somatic Mutations In Cancer,http://
cancer.sanger.ac.uk/cosmic) and ExAC (the Exome Aggregation Consortium, http://
exac.broadinstitute.org). A multiple sequence alignment was done with PRALINE program 
(http://www.ibi.vu.nl/programs/pralinewww/) using NCBI reference sequences. In silico 
structural models for STAT3 variants were based on the crystal structure of the mouse 
STAT3B homodimer bound to DNA (PDB ID: 1BG1) (Becker et al., 1998). Protein structure 
was visualized using the molecular graphics program PyMOL (PyMOL Molecular Graphics 
System, Version 1.8.4.0, Schrödinger, LLC, http://www.pymol.org/) which was also used to 
generate in silico the studied mutations. Side chain conformation for p.C426R was selected 
from the PyMOL backbone-dependent rotamer library that resulted in less steric clashes 
with surrounding residues.
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2.4. Site-directed mutagenesis
Gene variants were introduced into a commercial plasmid (pCMV6-Entry, RC215836, 
Origene, Rockville, MD, USA) containing the wild-type (WT) STAT3 cDNA 
(NM_139,276), using the Quick Change II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA, USA) and primers listed in Supplementary Table 1. All 
constructs were verified by sequencing.
2.5. Cell culture and transfections experiments
HEK293-T cells were routinely grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum, penicillin (100 units/mL), streptomycin (100 
μg/mL) and L-gluta-mine (2 mM) at 37 °C in a humidified atmosphere with 5% CO2. For 
transfection experiments, HEK293-T cells were seeded at a density of 2 × 105 cells/well in a 
24-multi well plate, grown to approximately 70–90% confluence, and transiently transfected 
with 500 ng Empty-pCMV6, or with a combination of 250 ng pcDNAI_Amp-GHRfl (Fang 
et al., 2008) and 250 ng vector carrying WT-STAT3 or variants using Lipofectamine 3000 
reagent (Invitrogen, Carlsbad, CA, USA). After 24 h transfection, cells were washed and 
serum starved for 6 h before a 15, 30 or 120-min treatment with 200 ng/mL recombinant 
human (rh) GH (Sandoz, Olivos, Argentina) or 20 ng/mL IL-6 (Gibco, Grand Island, NY, 
USA). Transfection experiments were performed in duplicates, at least three independent 
times.
2.6. Luciferase reporter assays
HEK293-T cells were seeded as described above and cotransfected with 125 ng of Cignal 
reporter assay constructs (Cignal STAT3 Reporter Assay kit (LUC), Qiagen, CA, USA), 
187.5 ng of WT or mutant STAT3 containing plasmids and 187.5 ng of pcDNAI_Amp-
GHRfl using the Lipofectamine 3000 transfection reagent. After 24 h transfection, cells 
were washed and serum starved for 6 h before 18-h treatment with 200 ng/mL rhGH or 20 
ng/mL IL-6. STAT3 reporter activity was assessed using a dual luciferase reporter assay 
system (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The 
renilla plasmid was used to normalize transfection efficiency. Results represent the ratio of 
reporter (firefly) to control (renilla) luciferase or are normalized as fold-change in the ratio 
as compared with WT-STAT3 plasmid. Data are presented as the mean ± SEM of five 
independent experiments. For evaluating STAT5b reporter activity in presence of STAT3 
GOF variants, HEK293-T cells expressing GHR were seeded as described above and 
transfected with a total input of 500 ng per well: 400 ng of the luciferase reporter construct 
carrying 8xGH response element (GHRE) from the rat Spi2.1 gene in pGL2 (pGHRE-LUC), 
50 ng of WT or mutant STAT3 containing plasmids and 50 ng of pCMV6-STAT5b (Origene, 
Rockville, US). After treatment with GH (200 ng/mL) for 18e24 h, collected cell lysates 
were analyzed for reporter activity using the luciferase assay system (Promega Corp., 
Madison, WI) following the manufacturer’s protocol. The results are presented as relative 
fold induction ± SEM, compared with activities detected in 20 mg total protein of untreated, 
pcDNA3.1-transfected cell lysates, which was given an arbitrary unit value of 1. Calculated 
values were from five independent experiments, performed in duplicate.
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2.7. Western immunoblot (WIB)
The effects of GH and IL-6 on STAT3 phosphorylation status in HEK293-T cells expressing 
GHR were examined by WIB analysis. Cells were starved for 6 h in serum-free medium and 
then stimulated with 200 ng/mL rhGH or 20 ng/mL IL-6 at 37 °C for 15, 30 and 120 min. 
After treatment, cells were washed with PBS and lysed in RIPA lysis buffer (1 × phosphate-
buffered saline, 1% v/v Nonidet P-40, 0.1% w/v SDS, 10 mg/mL phenylmethylsulfonyl 
fluoride, 1 mM sodium orthovanadate and protease inhibitor mixture). In a separate 
experiment designed to study dephosphorylation kinetics, after 30 min-treatment with 200 
ng/mL rhGH or 20 ng/mL IL-6 at 37 °C the stimuli were removed and the cells were washed 
with PBS and incubated for 15, 30 or 120 min at 37 °C in serum-free medium before 
solubilization. Extracts containing equal amounts of proteins, determined by the Bradford 
method (Bio-Rad, Michigan, USA), were separated by SDS-PAGE (12% acrylamide) and 
transferred to polyvinylidenedifluoride membranes (EMD Millipore, Billerica, MA, USA). 
Phosphorylation was detected using an anti-phospho-STAT3 (Tyr705) rabbit monoclonal 
antibody (Cell Signaling Technology, Danvers, MA, USA) and protein abundance of STAT3, 
using a rabbit monoclonal antibody against STAT3 (Cell Signaling Technology, Danvers, 
MA, USA). The signal was developed with donkey anti-rabbit IgG-horseradish peroxidase 
(GE Health-care Life Sciences, Freiburg, Germany) by chemiluminescence using 20 × 
LumiGLO Reagent (Cell Signaling Technology, Danvers, MA, USA). The intensities of 
autoradiographic bands were estimated by densitometric scanning using Image Studio™ Lite 
software (LI-COR Corporation, Lincoln, Nebraska USA).
2.8. Immunohistochemistry
HEK293-T cells were seeded as described above and transiently transfected with 500 ng 
Empty-pCMV6, or with a combination of 250 ng pcDNAI_Amp-GHRfl (Fang et al., 2008) 
and 250 ng vector carrying WT-STAT3 or variants using Lipofectamine 3000 reagent 
(Invitrogen, Carlsbad, CA, USA). After 24 h transfection, cells were washed and serum 
starved for 6 h before 120-min treatment with 200 ng/mL recombinant human (rh) GH 
(Sandoz, Olivos, Argentina). After GH treatment, cells were carefully washed with PBS and 
fixed with methanol:acetic acid (3:1) for 30 min followed by several washes in PBS. 
Immunostaining for phospho-Stat3 was performed using a rabbit monoclonal antibody 
(Phospho-Tyr705-Stat3; Cell Signaling Technology, Danvers, MA, USA) at a dilution 1:400, 
overnight at 4 °C. The immunohistochemical staining was performed manually at room 
temperature, using the avidin-biotinperoxidase complex method (Vectastatin Elite ABC kit; 
Vector Lab) following the manufacturer’s instructions. All the wells were lightly 
counterstained with hematoxylin for 30 s before dehydration and mounting. Digital images 
were acquired with a Cool Snap camera from Nikon and saved as .tif files. Images were 
taken randomly for counting the cells. Quantification of p-STAT3 (Tyr705) positive nuclei 
and total cells were manually performed from the images using Fiji Software (Schindelin et 
al., 2012). Minor adjustments in the captured images were performed identically and in 
parallel for the images presented using Corel Photo-Paint.
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2.9. Real time quantitative reverse transcriptase-PCR
For real time PCR, total RNA was extracted using TRI Reagent (Sigma-Aldrich, Carlsbad, 
CA, USA) according to the manufacturer’s recommendations. The amount of RNA was 
estimated by spectrophotometry at 260 nm. Reverse transcription (RT) was performed on 2 
μg RNA at 42 °C for 50 min using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, 
USA) containing 125 ng random primer and 0.5 mM dNTP Mix. The specificity of RT-PCR 
was evaluated by no template and no reverse-transcriptase controls. The cDNAs encoding 
SOCS3 were amplified from 1 μl of the cDNA reaction mixture using specific gene primers 
(Supplementary Table 2). qPCR was performed by a Step One Real Time PCR System 
(Applied Biosystems, Warrington, UK) using the FastStar Universal SYBR Green Master 
(ROX) (Merck KGaA, Darmstadt, Germany). Triplicate reactions were run for each sample 
and the data were normalized to human TBP (TATA-box binding Protein).
2.10. Statistical analysis
All experiments were repeated at least two times. Mean ± SEM of results from multiple 
experiments of the same study are reported. Results were analyzed with the t-test or Mann-
Whitney test for non-parametric data, as appropriate using Prism 5 (GraphPad Software, San 
Diego, CA) and significance was set at P < 0.05.
3. Results
3.1. Whole exome sequencing: two novel variants identified in the STAT3 gene
In patients 1 and 2, the short stature, immunological and endocrinological evaluations, 
suggested possible defects in the STAT5B (Hwa et al., 2011; Kofoed et al., 2003) and 
FOXP3 (van der Vliet and Nieuwenhuis, 2007; Wildin et al., 2001), respectively, but 
candidate gene analyses were unrevealing. WES analysis was, therefore, undertaken.
In patient 1, WES performed in a quartet-design (patient, parents and healthy sister) revealed 
42,639 variants in 13,110 genes. We applied different filtering strategies including mutation 
consequence (nonsense, missense, deletion or insertion in coding sequence), population 
frequency (<1%), inheritance pattern (auto-somal recessive or de novo) and a 250-candidate 
gene list considering the pathway involved. After a critical review of the literature and a final 
step of manual curation of the variants, a heterozygous in frame 3 bp deletion in STAT3 gene 
was the most likely candidate variant causing the observed phenotype of the patient. The 
variant c.1847_1849delAAG is predicted to result in deletion of glutamic acid 616 
(p.Glu616del), located in the SH2 domain of the protein.
WES analysis of Patient 2 and unaffected parents led to the identification of a private, de 
novo, heterozygous STAT3 variant, c.1276T > C, in exon 14, as the top candidate variant in 
the patient. The c.1276T > C generates a predicted missense substitution, p.Cys426Arg, in 
the DNA binding domain of the protein.
Analysis of parental DNA samples showed that both mutations had arisen de novo. 
According to bioinformatic algorithms and the ACMG recommendations (Richards et al., 
2015), both variants were classified as likely pathogenic (Supplementary Table 3). The 
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variant p.E616del has only been reported as a somatic mutation causing large granular 
lymphocytic (LGL) leukemia (COSMIC database) whereas variant p.C426R is absent from 
public databases of genetic variation (dbSNP, ExAC and COSMIC). The analysis of 
positional conservation of STAT3 residues by multiple sequence alignment from six species 
(human, chimpanzee, rhesus, mouse, chicken and zebrafish) showed that both residues C426 
and E616 are highly conserved within the DNA binding and the SH2 domains, respectively, 
among species (Fig. 1). The E616 is also conserved among STAT1 and STAT2, in contrast to 
C426 which is not conserved among STATs proteins. Fig. 2A shows an illustration of the 
three-dimensional structure of the mouse Stat3b homodimer bound to DNA. The residues 
corresponding to the reported variants are shown in magenta. C426 is located in a region 
without known structure, within a stretch of 19 amino acids that is flanked by ß-sheets. 
Although E616 is located within the SH2 domain, it is close to the DNA binding surface and 
interactions between the STAT3 protein and the DNA duplex may involve this residue (Fig. 
2A).
3.2. STAT3 p.E616del and p.C426R are constitutively activated variants that further 
increase their transcriptional activities in response to GH
To investigate possible functional consequences of p.E616deland p.C426R-STAT3 variants, 
we evaluated the activity of each mutant using a STAT3-responsive dual-luciferase reporter 
assay. Constructs encoding a previously identified STAT3 mutation, a loss-of-function -
LOF- mutation described in hyper IgE syndrome, p.R423Q (Hsu et al., 2007), and WT-
STAT3 were generated and transiently transfected into cultured HEK293-T cells expressing 
GHR. Expression of p.E616del and p.C426R mutants resulted in a significant increase in 
reporter activity (P < 0.05) in comparison to WT-STAT3 or LOF-STAT3 under non-
stimulated conditions (Fig. 3A), suggesting that these mutants are constitutively activated. 
The effect of GH on the transcriptional activity of p.E616del and p.C426R was also 
evaluated. In WT-STAT3 transfected cells, GH stimulation resulted in an 8-fold increase 
above basal levels. For constitutively activated p.E616del and p.C426R, GH treatment 
increased luciferase activities by 2- to 4-fold above the levels observed for WT-STAT3 (Fig. 
3B). Although HEK293-T constitutively express GHR, in our system GH was not able to 
stimulate luciferase production in cells not overexpressing GHR (data not shown). These 
results suggest that GH stimulation is specifically mediated by the GH receptor. IL-6 
stimulation of WT-STAT3 induced the luciferase reporter gene 15-to 20-fold (Fig. 3C). Both 
p.C426R and p.E616del variants showed ~2- to 2.5-fold increase in reporter activity under 
IL-6 stimulation (Fig. 3B). However, the fold change relative to WT-STAT3 was 
significantly higher only for p.C426R variant (Fig. 3C).
3.3. The STAT3 variants are not constitutively phosphorylated and demonstrate different 
dephosphorylation patterns under GH and IL-6 treatments
To further study the differences in the activation of p.E616del and p.C426R, we evaluated 
the effects of IL-6 and GH on Y705-STAT3 phosphorylation by WIB. Under basal 
conditions (unstimulated), STAT3 was not phosphorylated in either mutant (Fig. 4). 
WTSTAT3 and both variants were phosphorylated in response to IL-6 and GH and 
dephosphorylation was not observed within the first 30 min of stimulation (Fig. 4A and B). 
Phosphorylated 705Tyr-STAT3 was still detectable up to 120 min of treatment. However, at 
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this time-point, phosphorylation was diminished for WT-STAT3 (Fig. 4A and B). A similar 
temporal pattern was observed for p.R423Q. This inactivating substitution is located in the 
DNA binding domain and the STAT3 loss of function is not a consequence of altered 
phosphorylation, as was previously reported (Minegishi et al., 2007).
Both STAT3 activating mutants exhibited different dephosphorylation kinetics under GH and 
IL-6 treatments. While p.C426R exhibited delayed dephosphorylation only under GH 
treatment (Fig. 4A), p.E616del showed delayed dephosphorylation only when stimulated 
with IL-6 (Fig. 4B). To study differences in STAT3 dephosphorylation kinetics, we removed 
GH or IL-6 stimuli after 30 min of treatment and cell lysates were then collected 15, 30 and 
120 min after removal of the stimuli. Cell lysates were analyzed by WIB (Fig. 4C and D). 
No differences regarding the temporal dephosphorylation pattern were observed for WT-
STAT3 and p.R423Q when GH or IL-6 were depleted from the media. In contrast to the 
previous observed results when GH and IL-6 stimuli were maintained, no delayed 
dephosphorylation was observed for p.C426R and p.E616del once the stimuli were depleted 
from the media (Fig. 4C and D).
In agreement with WIB results, immunohistochemical (IHC) analysis showed a significantly 
increased presence of phospho-STAT3 positive nuclei after 2 h of GH-stimulation in cells 
transfected with p.C426R variant in comparison to those transfected with WT-STAT3 (Fig. 
5).
3.4. STAT5b function is partially impaired in presence of STAT3 activating variants
Since patients carrying these variants have growth retardation, we next decided to explore 
the impact of p.C426R and p.E616del STAT3 variants on STAT5b activity, a key 
intracellular mediator of the GH actions and inductor of IGF-1 transcription. HEK293-T 
cells overexpressing GHR were co-transfected with WT-STAT3 or variants and a plasmid 
encoding STAT5b in equimolar proportions. Transcriptional activity of STAT5b was 
evaluated by using a lucif-erase reporter assay. STAT5b transcriptional activity was 
diminished in the presence of STAT3 GOF variants under unstimulated conditions (p < 0.05) 
(Fig. 6A). The activity of STAT5b in cells expressing STAT3 activating variants was 
increased ~30-fold in response to GH, nonetheless this increase was significantly lower than 
in the presence of WT-STAT3 (Fig. 6B). Because activation of STAT5b can be negatively 
regulated by SOCS3, one of the major targets of STAT3, we evaluated SOCS3 mRNA levels 
in our system. We found that SOCS3 transcription levels were induced for both activating 
variants under unstimulated conditions (p < 0.05) but only p.E616del showed a >1.5-fold 
change in SOCS3 mRNA levels (p < 0.01) under GH treatment (Fig. 7).
4. Discussion
In this study, we presented two novel cases of IGF-I deficiency, severe short stature and 
immune dysregulation due to activating germline STAT3 mutations identified by WES. The 
two patients shared clinical features such as autoimmune hypothyroidism, dermatitis, 
chronic diarrhea and recurrent infections. They present a clinical phenotype overlapping 
with previously described patients with STAT3 GOF mutations (Flanagan et al., 2014; 
Haapaniemi et al., 2015; Milner et al., 2015), as well as some clinical similarities to other 
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monogenic immune dysregulation disorders, including autoimmune lymphoproliferative 
syndrome (ALPS), immunodeficiency polyendocrinopathy enteropathy x-linked (IPEX), 
IPEX-like disorders, and STAT5b-deficiency. Of note, patients with STAT5B LOF mutations 
present severe postnatal growth failure and marked IGF-I deficiency as consequences of 
complete GH insensitivity, including poor responsiveness to GH treatment (Kofoed et al., 
2003). In contrast, patient 1 had a good response to GH therapy. Good response to GH 
treatment was also reported in 2 other patients with activating STAT3 mutations (Milner et 
al., 2015).
P1 died after hematopoietic stem cell transplantation (SCT). Unfortunately, SCT was also 
unsuccessful in two out of three other patients, who succumbed shortly after the procedure 
(Haapaniemi et al., 2015; Milner et al., 2015; Sediva et al., 2017). This suggests that other 
therapeutic approaches, such as specific small-molecule STAT3 inhibitors, are perhaps more 
appropriate therapies for these patients.
To evaluate the impact of these mutations on STAT3 structure and activity we performed in 
silico and in vitro studies. Sequence alignments showed that C426 residue is located in a 
region containing basic amino acids in all STAT family proteins. STAT5a, 5b and 6 have an 
arginine residue in the equivalent position to STAT3 C426 (Fig. 1), suggesting that the 
change C426R in the STAT3 could be structurally tolerated. In silico mutagenesis of C426 
by arginine using Pymol backbone-dependent rotamer library is predicted to cause an 
increase in the hydrophobicity in this region, compared to WT-STAT3 (Fig. 2B). Moreover, 
the calculation of electrostatic potential reveals an increase in the positively charged surface 
on the DNA-binding interface on p.C426R (Fig. 2C), as expected for the substitution of 
cysteine for the positively charged arginine residue. Likewise, in silico deletion of E616 
predicts an increase in the positive electrostatic potential at the proximity of the DNA-
binding surface (Fig. 2C). Therefore, both mutations would enhance the electrostatic 
interaction with the negatively charged DNA phosphate backbone, suggesting an increase in 
DNA binding affinity and, consequently, increased STAT3 transcriptional activities.
In vitro characterization of both variants indicated they were GOF variants since they 
activate STAT3 signaling pathway in absence of stimuli. As far as we know, the variant 
p.E616del is the only activating deletion in STAT3 described in patients with this syndrome. 
Although E616 is located within the SH2 domain, using molecular dynamics simulations 
Husby et al. predicted E616 as a key residue of monomer-B involved in STAT3 protein-DNA 
interaction (Husby et al., 2012), consistent with our molecular modelling. Therefore, 
enhanced activity of both variants, p.C426R and p.E616del, might be a consequence of 
electrostatic effects caused by the gain of positive charges at the DNA-binding surface, 
leading to increased DNA binding affinity and prolonged nuclear retention. However, each 
mutant responded differently to GH and IL-6 in vitro. When treated with IL-6, the 
transcriptional activity of p.E616del increased compared to unstimulated conditions. 
Nonetheless, this increase was lower than levels reached for WT-STAT3. This result is 
consistent with previously reported STAT3 mutations located within the same region, 
p.N646K (Flanagan et al., 2014) and p.T663I (Milner et al., 2015), where the significant 
increase in reporter activity under basal conditions was not above the levels reached by WT-
STAT3 after stimulation with IL-6. In contrast, p.C426R had markedly elevated basal 
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activity which was further increased with GH and IL-6 stimulation, as reported for other 
mutations in the DNA binding domain, as well as in the other protein domains (Flanagan et 
al., 2014; Haapaniemi et al., 2015; Milner et al., 2015). Therefore, increased basal STAT3 
activity does not imply that response to a stimulus is also increased. The response will most 
likely depend on the type and location of the mutation and on the stimulus applied. In 
accordance with these findings, dephosphorylation patterns were different for each variant 
depending on the treatment. The p.C426R variant showed delayed dephosphorylation only 
under GH stimulus, in line with IHC results. Conversely, for p.E616del variant, delayed 
dephosphorylation was observed only when stimulated with IL-6. Delayed 
dephosphorylations were not observed once the stimuli were removed, which suggests that 
both variants are accessible to nuclear phosphatases that recycle STAT proteins back to the 
cytoplasm and mutations are not affecting phosphatases recognition processes.
The mechanism underlying these dephosphorylation patterns could probably involve the 
increased DNA affinity, as we already mentioned above, which induces a faster DNA 
binding (on-rate) and sensitizes STAT3 to cytokine stimulation, followed by a slow off-rate, 
which protects it from inactivation by phosphatases, as has been also suggested for the 
constitutively activated oncogenic Stat3 mutant (Stat3-C) (Li and Shaw, 2006). However, it 
is possible that the critical intracellular concentration of activated STAT3 needed to elicit the 
cellular response varies depending on the nature of each STAT3 mutation. Furthermore, 
other factors such as changes in partners involved in heterodimer formation and variations in 
co-activators and co-repressors recruitment, could also impact on the final transcriptional 
activity. Altogether, these aspects could also contribute to the broad spectrum of clinical 
manifestations among patients.
We also explored how these variants affect STAT5b in the GH signaling pathway. In most 
cell types, STAT5b and STAT3 play divergent and opposing effects on gene expression 
(Akira, 1999; Herrington et al., 2000). A previous study showed decreased STAT5 
phosphorylation in patient-derived EBV-transformed cell lines carrying a STAT3 activating 
mutation (Milner et al., 2015). The authors suggest that STAT5 is negatively regulated by 
SOCS3, one of the major targets of STAT3. We found that SOCS3 transcription levels were 
induced for both GOF variants under unstimulated conditions but only p.E616del showed a 
significant increase in SOCS3 mRNA levels under GH treatment. This result is consistent 
with dephosphorylation patterns observed by WIB for both variants. Increased levels of 
SOCS3 for p.E616del in response to GH, could lead to a decrease in STAT3 phosphorylation 
via JAK2, as we detected by WIB. In contrast, p.C426R presented similar SOCS3 transcript 
levels under basal and stimulated conditions, in agreement with delayed dephosphorylation 
under GH treatment. Nonetheless, STAT5b transcriptional activity was partially impaired in 
presence of STAT3 GOF variants, both under unstimulated conditions and under GH 
treatment. These findings suggest that enhanced activity of STAT3 variants in response to 
GH decrease STAT5b function by slightly different mechanisms, leading to partial GH 
insensitivity. Further studies are necessary to elucidate the underlying mechanisms, that can 
include the formation of nonfunctional STAT5b/STAT3 heterodimers, competition for 
common receptor docking sites and regulation for posttranslational epigenetic modifications, 
as was recently described for GOF-STAT1 mutations and their effects on STAT3 function 
(Zheng et al., 2015).
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Heterozygous STAT3 GOF mutations result in a broad spectrum of clinical phenotypes, 
involving infectious and autoimmune diseases, growth failure and IGF-I deficiency. No clear 
genotype/phenotype correlation has been observed. In some inherited reported cases, family 
members carrying the same STAT3 GOF mutation presented a milder phenotype, or were 
even asymptomatic, suggestive of incomplete penetrance (Milner et al., 2015). However, 
short stature is a key clinical finding in these patients. To our knowledge, 15 out of 22 
reported patients with available growth data (Flanagan et al., 2014; Haapaniemi et al., 2015; 
Milner et al., 2015; Sediva et al., 2017; Velayos et al., 2017; Weinreich et al., 2017) (~68%, 
including our patients) had growth impairment (Supplementary Table 4 and Supplementary 
Fig. 2) and our in vitro studies suggest a disruptive role of STAT3 GOF variants in the GH 
signaling pathway. Accordingly, STAT3 activating mutations has already been considered an 
additional monogenic cause of primary IGF-I deficiency (Wit et al., 2015). Nonetheless, it is 
not entirely possible to rule out the potential secondary deleterious effects of the immune 
dysregulation (diabetes, hypothyroidism, recurrent infections) and the pharmacological 
treatments on the growth rate in these patients. As the effect of STAT3 GOF mutations on 
the clinical phenotype is difficult to accurately predict, our present report emphasizes the 
importance of complementing genetic analysis with functional studies, for a better 
understanding of potential therapeutic approaches.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Schematics of human STAT3. The position of the two de novo mutations are shown below 
the STAT3 domains. Multiple sequence alignments among different species and among 
STAT proteins were done with PRALINE software. The color scheme indicates the least 
conserved alignment position (dark blue), to the most conserved alignment position (red). 
(For interpretation of the references to color in this figure legend, the reader is referred to the 
Web version of this article.)
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Fig. 2. 
A) Structural model of the STAT3 dimer bound to DNA (PDB ID: 1BG1) (Becker et al., 
1998) in cartoon representation. Individual domains are color coded as in Fig. 1 only on the 
left chain. Variant residues under study are shown as space-filling mode in magenta. B) The 
structure has been rotated and expanded to show residues E616 and C426 (sticks) close to 
the DNA duplex surface. C) Surface representation of the predicted hydrophobicity of WT-
STAT3 (left) and variants p.C426R (center) and p.E616del (right). Coloring was achieved 
using the color_h.py python script in Pymol, and the color scale is based on the Eisenberg 
normalized hydrophobicity scale (Eisenberg et al., 1984) where hydrophilic residues are 
lighter/white, and hydrophobic residues are darker/red. Both variants show an increase in the 
hydrophobicity surface in regions where the residues were substituted or deleted. D) 
Electrostatic potentials are mapped onto the molecular surfaces of WT-STAT3 and mutants, 
with negative potentials colored red and positive potentials colored blue. The electrostatic 
potentials were calculated and visualized using APBS plugin -Adaptive PoissoneBoltzmann 
Solver (Baker et al., 2001)- in Pymol. The variants (center and right) show an increase in the 
positive electrostatic potential on the DNA binding surface compared to WT-STAT3 (left). 
(For interpretation of the references to color in this figure legend, the reader is referred to the 
Web version of this article.)
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Fig. 3. 
STAT3 transcriptional activity determined by luciferase reporter assay. A) STAT3 activity of 
WT and variants, p.E616del, p.C426R and LOF variant, p.R423Q, under non-stimulated 
conditions. Data represents the mean ratio of firefly/control luciferase activity for each 
construct ± SEM (n = 5). B) STAT3 activity of WT and mutants following 18 h activation 
with GH (200 ng/mL, black) or IL-6 (20 ng/mL, gray). Data are presented as average fold of 
change relative to WT ± SEM of at least 5 independent experiments. The dotted line 
represents a fold-change of 1 (no change from WT). C) The same experiment as B) but data 
are presented as the mean ratio of firefly/control for each construct ± SEM (n = 5) under GH 
(200 ng/mL, black) or IL-6 (20 ng/mL, gray) 18-h treatment in comparison with 
unstimulated conditions. *P < 0.05, **P < 0.01, ***P < 0.001, t-test.
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Fig. 4. 
Western Blot of STAT3 expression and phosphorylation. WT-STAT3 and mutants were 
transfected in HEK293-T cells expressing GHR and p-STAT3 and total STAT3 were 
determined under basal (B, 0 min) or stimulated conditions (15, 30, 120 min). GH (200 
ng/mL) (A) and IL-6 (20 ng/mL) (B) induced phosphorylation of WT-STAT3 and mutants. 
p-STAT3 and total STAT3 were additionally evaluated at 15, 30 and 120 min after removing 
a 30-min treatment with GH (+, 200 ng/mL) (C) and IL-6 (+, 20 ng/mL) (D). β-tubulin was 
used as loading control. p-STAT3, phosphorylated STAT3. The upper panels show 
representative autoradiographies out of three. The lower panels show pooled data of three 
independent experiments indicating the fold variation in phosphorylation (ratio of p-STAT3 
to total STAT3 in each sample) relative to WT-STAT3 for each time point. Results are 
expressed as means ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, t-test.
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Fig. 5. 
HEK293-T cells overexpressing WT-STAT3 and variants were examined 
immunohistochemically for p-STAT3 (tyr705) detection under unstimulated conditions 
(upper panels) and after 2 h-GH treatment (200 ng/mL, lower panels). Number of positive p-
STAT3 nuclei were normalized to total cells and expressed as Mean ± SEM from at least six 
random microscopic field images of two independent experiments. Mann-Whitney test (*P < 
0.05) was used to compare positive p-STAT3 nuclei between cells expressing STAT3-GOF 
variants and WT-STAT3. Representative images are shown (Magnification 40 ×).
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Fig. 6. 
STAT5b transcriptional activity in presence of WT-STAT3 or variants determined by 
luciferase reporter assay. (A) STAT5b activity in presence of WT-STAT3, p.C426R and 
p.E616del STAT3 variants under non-stimulated conditions. (B) Cells co-transfected with 
STAT5b, WT-STAT3 or variants, and pGHRE-LUC were treated with GH (200 ng/mL, 18 h) 
and cell lysates were analyzed for luciferase activities. Luciferase activities were normalized 
to total protein and expressed as Mean ± SEM from at least five independent experiments, 
each performed in duplicates. The normalized luciferase activity for Empty-pcDNA3.1 was 
set to an arbitrary value of 1. Relative induction of STAT5b transcriptional activity in 
presence of STAT3-GOF variants was compared to that in presence of WT-STAT3 using 
Mann-Whitney test (*P < 0.05 and **P < 0.01 vs. WT-STAT3).
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Fig. 7. 
SOCS3 mRNA levels were determined under unstimulated conditions or after 18 h-GH 
treatment (200 ng/mL) in HEK293-T cells expressing WT-STAT3 or variants. SOCS3 
transcript levels were normalized to TBP. Data represent the mean ± SEM, n = 3. *P < 0.05, 
**P < 0.01, t-test.
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Table 1
Clinical characteristics of patients with de novo STAT3 mutations.
Patient 1 (female) Patient 2 (male)
Birth Gestational Age (weeks) 38 38
Birth weight (g) 3155 3586
Birth length (cm/SDS) 44 (−2.76) 50.8 (−0.75)
First visit Chronological Age (years) 2.5 3.0
Height (SDS) −6.4 −5.4
Weight (SDS) −3.4 −2.7
Clinical features Congenital autoimmune 
hypothyroidism, descamative 
eczema, chronic diarrhea, recurrent 
oral candidiasis, severe respiratory 
infections
History of IPEX-like 
syndrome with dermatitis, 
chronic diarrhea, colitis, 
autoimmune 
hypothyroidism
Immunological evaluation IgG (RR: 760–1348mg/dL) 637 760
IgA(RR: 40–132 mg/dL) 389 211
IgM (RR: 79–131 mg/dL) (mg/dL) 103 134
IgE (RR: 8–32 UI/mL) <5 <1
CD3/CD4/CD8/CD19/CD3CD56(%) 49/34/14/42/8 82/35/45/12/nd
FOXP3/Treg CD127/Thl7 N/N/low N/N/N
Endocrine evaluation GH (ng/ml) 20 -
IGF-I (ng/ml) basal (RR: 35–160) <12 <25
post 1GF-GT (rhGH for 7d) 20
IGFBP-3 (ng/ml) basal (RR: 1.7–4.2) 1.0 0.5
post 1GF-GT (rhGH for 7d) 2.2
Prolactin (ng/ml) (RR: 2–15) 30,6
TSH (mlU/ml) (RR: 0.5–6.5) 238 364
FT4 (ng/dl) (RR: 0.8–2.0) 0.4 0.2
TPO-Ab/TG-Ab (IU/ml) (RR:<20/<20) 83/48 >1000/165
rhGH treatment Dose 0.43 mg/kg.wk 0.3 mg/kg.d
Height gain (SDS)/Period (years) 1.4/2 0.42/1.4
IGF-I (ng/ml) 240
IGFBP-3 (ng/ml) 4.4
Molecular studies WES: Heterozygous de novo STAT3 
variants
c.l847_1849delAAG (p.Glu616del) C.1276T>C (p.Cys426Arg)
SH2 domain DNA binding domain
RR: Reference range. N: Normal. nd: Not determined.
For Patient 1, height SDS was based on Argentinean growth references (Lejarraga et al., 2009) and for Patient 2, on 2000 CDC growth charts 
(Kuczmarski et al., 2002).
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